Mankind Pharma Share Price

  • 2,425.95-2.61 (-0.11%)
NSE
  • Closed
  • As On: 29 Aug, 2024, 03:59 PM IST
STOCK SCORE
Unlock Scores
Add to Watchlist
  • Open2,421.00
  • High2,448.00
  • Low2,408.00
  • Prev Close2,428.55
  • Volume2,66,558
  • VWAP(₹)2,425.87

Mankind Pharma share price insights

Rank 219 - ET 5002023 ranking

  • Intraday fact check

    Since its listing, only 1.22 % trading sessions saw intraday declines higher than 5 % .

  • Employee & Interest Expense

    Company has spent less than 1% of its operating revenues towards interest expenses and 22.01% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Mankind Pharma Share Price Update

    Mankind Pharma Ltd. share price moved down by -0.11% from its previous close of Rs 2,428.55. Mankind Pharma Ltd. stock last traded price is 2,425.95

    Share PriceValue
    Today/Current/Last2,425.95
    Previous Day2,428.55

Mankind Pharma Share Price Returns

1 Day-0.11%
1 Month17.59%
3 Months15.39%
1 Year36.08%
3 YearsN.A.
5 YearsN.A.

Key Metrics

PE Ratio(x)49.52
EPS - TTM(₹)48.99
MCap(₹ Cr.)97,192.08
MCap Rank8
PB Ratio(x)10.16
Div Yield(%)0.00
Face Value(₹)1.00
52W High(₹)2,490.00
52W Low(₹)1,683.05
MCap/Sales8.90
Beta(1 Month)N.A.
BV/Share(₹)239.02

Mankind Pharma Share Recommendations

Mean recosCurrent
BUY

12 Analysts

Strong
SellSellHoldBuyStrong
Buy
Analyst Trends
RatingsCurrent1W Ago1M Ago3M Ago
Strong Buy2222
Buy5555
Hold4444
Sell1111
Strong Sell----
# Analysts12121212
Recent Recos
  • Target₹2760
  • OrganizationMotilal Oswal Financial Services
  • BUY
View all Stock Recommendations
ADVERTISEMENT

Mankind Pharma News & Analysis

View all Mankind Pharma Share News & Announcements
ADVERTISEMENT

Mankind Pharma Financials

Consolidated
  • Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Income2,994.022,533.232,677.092,768.082,637.24
    Total Income Growth (%)18.19-5.37-3.294.9625.57
    Total Expenses2,319.401,954.682,110.182,121.942,011.16
    Total Expenses Growth (%)18.66-7.37-0.555.5116.89
    EBIT674.62578.54566.91646.14626.08
    EBIT Growth (%)16.612.05-12.263.2064.90
    Profit after Tax (PAT)536.49471.24453.76501.03494.19
    PAT Growth (%)13.853.85-9.431.3873.13
    EBIT Margin (%)22.5322.8421.1823.3423.74
    Net Profit Margin (%)17.9218.6016.9518.1018.74
    Basic EPS (₹)13.3911.7611.3312.5112.15
    Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Income2,498.092,236.542,425.802,511.462,357.65
    Total Income Growth (%)11.69-7.80-3.416.5223.14
    Total Expenses1,914.461,687.651,845.191,895.191,829.29
    Total Expenses Growth (%)13.44-8.54-2.643.6017.39
    EBIT583.63548.89580.61616.27528.36
    EBIT Growth (%)6.33-5.46-5.7916.6448.28
    Profit after Tax (PAT)513.49454.17487.07472.88409.28
    PAT Growth (%)13.06-6.763.0015.5445.66
    EBIT Margin (%)23.3624.5423.9324.5422.41
    Net Profit Margin (%)20.5620.3120.0818.8317.36
    Basic EPS (₹)12.8211.3412.1611.8010.22
    FY 2024FY 2023FY 2022FY 2021
    Total Revenue10,615.638,878.007,977.586,385.38
    Total Revenue Growth (%)19.5711.2924.946.86
    Total Expenses8,231.497,219.186,017.434,705.45
    Total Expenses Growth (%)14.0219.9727.883.43
    Profit after Tax (PAT)1,912.901,281.861,433.481,265.43
    PAT Growth (%)49.23-10.5813.2822.81
    Operating Profit Margin (%)23.3919.4625.9427.35
    Net Profit Margin (%)18.5014.6518.4220.36
    Basic EPS (₹)47.7532.0035.7831.59
    FY 2024FY 2023FY 2022FY 2021FY 2020
    Total Revenue9,531.458,289.947,419.775,677.684,888.26
    Total Revenue Growth (%)14.9811.7330.6816.1524.01
    Total Expenses7,271.886,727.105,622.234,237.473,623.34
    Total Expenses Growth (%)8.1019.6532.6816.9511.47
    Profit after Tax (PAT)1,823.411,248.261,335.131,084.37958.23
    PAT Growth (%)46.08-6.5123.1213.1686.41
    Operating Profit Margin (%)24.5419.5725.3726.1826.60
    Net Profit Margin (%)19.6815.3518.3919.6119.98
    Basic EPS (₹)45.5231.1633.3327.0723.92

    All figures in Rs Cr, unless mentioned otherwise

    Insights

    • Employee & Interest Expense

      Company has spent less than 1% of its operating revenues towards interest expenses and 22.01% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
  • AnnualFY 2024FY 2023FY 2022FY 2021
    Total Assets11,963.259,715.459,147.746,372.63
    Total Assets Growth (%)23.146.2143.5525.61
    Total Liabilities2,387.472,092.162,831.431,509.74
    Total Liabilities Growth (%)14.12-26.1187.547.71
    Total Equity9,575.797,623.296,316.314,862.89
    Total Equity Growth (%)25.6120.6929.8932.45
    Current Ratio (x)3.102.321.682.89
    Total Debt to Equity (x)0.020.020.140.05
    Contingent Liabilities329.78167.78211.93183.16
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Total Assets11,417.719,371.128,412.855,880.334,531.11
    Total Assets Growth (%)21.8411.3943.0729.7817.02
    Total Liabilities1,793.901,587.212,344.071,146.06879.65
    Total Liabilities Growth (%)13.02-32.29104.5330.298.98
    Total Equity9,623.817,783.916,068.774,734.273,651.45
    Total Equity Growth (%)23.6428.2628.1929.6519.14
    Current Ratio (x)3.452.481.462.862.39
    Total Debt to Equity (x)0.000.000.110.020.00
    Contingent Liabilities449.91168.37275.47--

    All figures in Rs Cr, unless mentioned otherwise

  • AnnualFY 2024FY 2023FY 2022FY 2021
    Net Cash flow from Operating Activities2,152.451,813.30919.781,137.24
    Net Cash used in Investing Activities-2,081.69-1,054.13-1,369.14-1,222.21
    Net Cash flow from Financing Activities5.27-739.73604.62-7.81
    Net Cash Flow77.1921.76155.73-92.40
    Closing Cash & Cash Equivalent382.01304.82283.06127.33
    Closing Cash & Cash Equivalent Growth (%)25.327.69122.31-42.05
    Total Debt/ CFO (x)0.090.090.950.21
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Net Cash flow from Operating Activities1,982.971,798.99812.291,022.33959.61
    Net Cash used in Investing Activities-1,919.12-1,040.61-1,369.34-1,127.16-395.68
    Net Cash flow from Financing Activities-8.68-710.41578.9288.87-558.91
    Net Cash Flow55.0747.9621.87-15.965.02
    Closing Cash & Cash Equivalent189.20134.1344.4561.5377.50
    Closing Cash & Cash Equivalent Growth (%)41.06201.76-27.76-20.606.92
    Total Debt/ CFO (x)0.000.000.850.090.00

    All figures in Rs Cr, unless mentioned otherwise

    Insights

    • Increase in Cash from Investing

      Company has used Rs 2081.69 cr for investing activities which is an YoY increase of 97.48%. (Source: Consolidated Financials)
  • AnnualFY 2024FY 2023FY 2022FY 2021
    Return on Equity (%)20.4317.2423.2826.79
    Return on Capital Employed (%)24.5621.6930.9433.87
    Return on Assets (%)15.9813.1915.6719.85
    Interest Coverage Ratio (x)83.9845.6337.2990.29
    Asset Turnover Ratio (x)0.950.880.981.01
    Price to Earnings (x)48.31---
    Price to Book (x)9.83---
    EV/EBITDA (x)32.40---
    EBITDA Margin (%)27.2423.1928.0829.27
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Return on Equity (%)18.9416.0322.0022.9026.24
    Return on Capital Employed (%)23.1420.0029.7730.1634.33
    Return on Assets (%)15.9713.3215.8718.4421.14
    Interest Coverage Ratio (x)177.8867.0444.77191.27125.97
    Asset Turnover Ratio (x)0.890.911.021.061.14
    Price to Earnings (x)50.51----
    Price to Book (x)9.56----
    EV/EBITDA (x)35.21----
    EBITDA Margin (%)27.9722.8827.0427.6027.89
ADVERTISEMENT

Peer Comparison

Mutual Funds Ownership

No Data Available

ADVERTISEMENT

Corporate Actions

  • Board Meeting

    Quarterly Results

    Jul 18, 2024

    Board Meeting

    Audited Results & Others

    May 08, 2024

    Board Meeting

    Quarterly Results

    Jan 16, 2024

  • Announced onMeeting on
    Jul 18, 2024Jul 31, 2024
    Quarterly Results
    May 08, 2024May 15, 2024
    Audited Results & Others
    Jan 16, 2024Jan 31, 2024
    Quarterly Results
    Oct 11, 2023Oct 31, 2023
    Quarterly Results
    Jul 18, 2023Aug 02, 2023
    Quarterly Results

  • No Data Available

  • No Data Available

  • No Data Available

  • No Data Available

  • Announced onMeeting on
    Aug 02, 2023Sep 22, 2023
    -
ADVERTISEMENT

About

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 97,192.08 Crore) operating in Pharmaceuticals sector.

Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Royalty Income for the year ending 31-Mar-2024.

For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 2,994.02 Crore, up 18.19 % from last quarter Total Income of Rs 2,533.23 Crore and up 13.53 % from last year same quarter Total Income of Rs 2,637.24 Crore. Company has reported net profit after tax of Rs 539.16 Crore in latest quarter.

The company’s top management includes Mr.Ramesh Juneja, Mr.Ramesh Juneja, Mr.Rajeev Juneja, Mr.Rajeev Juneja, Ms.Sheetal Arora, Ms.Sheetal Arora, Mr.Satish Kumar Sharma, Mr.Satish Kumar Sharma, Mr.Bharat Anand, Mr.Bharat Anand, Mr.Surendra Lunia, Mr.Surendra Lunia, Mr.Tilokchand Punamchand Ostwal, Mr.Tilokchand Punamchand Ostwal, Ms.Vijaya Sampath, Ms.Vijaya Sampath, Mr.Vivek Kalra, Mr.Vivek Kalra, Mr.Ashutosh Dhawan, Mr.Arjun Juneja, Mr.Pradeep Chugh. Company has S R Batliboi & Co. LLP as its auditors. As on 30-06-2024, the company has a total of 40.06 Crore shares outstanding.

About Mankind Pharma

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 97,192.08 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Royalty Income for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 2,994.02 Crore, up 18.19 % from last quarter Total Income of Rs 2,533.23 Crore and up 13.53 % from last year same quarter Total Income of Rs 2,637.24 Crore. Company has reported net profit after tax of Rs 539.16 Crore in latest quarter.The company’s top management includes Mr.Ramesh Juneja, Mr.Ramesh Juneja, Mr.Rajeev Juneja, Mr.Rajeev Juneja, Ms.Sheetal Arora, Ms.Sheetal Arora, Mr.Satish Kumar Sharma, Mr.Satish Kumar Sharma, Mr.Bharat Anand, Mr.Bharat Anand, Mr.Surendra Lunia, Mr.Surendra Lunia, Mr.Tilokchand Punamchand Ostwal, Mr.Tilokchand Punamchand Ostwal, Ms.Vijaya Sampath, Ms.Vijaya Sampath, Mr.Vivek Kalra, Mr.Vivek Kalra, Mr.Ashutosh Dhawan, Mr.Arjun Juneja, Mr.Pradeep Chugh. Company has S R Batliboi & Co. LLP as its auditors. As on 30-06-2024, the company has a total of 40.06 Crore shares outstanding.

Industry

Pharma - Indian

Key Indices Listed On

Nifty Midcap 100, Nifty 200, Nifty 500, BSE 500, Nifty Pharma

Address

208, Okhla Industrial Estate,Phase-III,New Delhi, Delhi - 110020

Contact

investors@mankindpharma.com

http://www.mankindpharma.com

Executive Leadership

RJ

Ramesh Juneja

Chairman & Wholetime Director
RJ

Ramesh Juneja

Chairman & Wholetime Director
RJ

Rajeev Juneja

Vice Chairman & Mng.Director
RJ

Rajeev Juneja

Vice Chairman & Mng.Director
Show More

Auditors

Bhagi Bhardwaj Gaur & Co
S R Batliboi & Co. LLP
Goel Gaurav & Co.

FAQs about Mankind Pharma share

  • 1. What is Mankind Pharma share price and what are the returns for Mankind Pharma share?
    Mankind Pharma share price was Rs 2,425.95 as on 29 Aug, 2024, 03:59 PM IST. Mankind Pharma share price was down by 0.11% based on previous share price of Rs 2,427.1. Mankind Pharma share price trend:
    • Last 3 Months: Mankind Pharma share price moved up by 15.39%
    • Last 12 Months: Mankind Pharma share price moved up 36.08%
    • Last 3 Years: Mankind Pharma Share price moved remain unchanged by N.A.
  • 2. Who is the chairman of Mankind Pharma?
    Ramesh Juneja is the Chairman & Wholetime Director of Mankind Pharma
  • 3. Who is the CEO of Mankind Pharma?
    Sheetal Arora is the WholeTime Director & CEO of Mankind Pharma
  • 4. What are the returns for Mankind Pharma share?
    Return Performance of Mankind Pharma Shares:
    • 1 Week: Mankind Pharma share price moved up by 4.58%
    • 3 Month: Mankind Pharma share price moved up by 15.39%
    • 6 Month: Mankind Pharma share price moved up by 13.60%
  • 5. What has been highest price of Mankind Pharma share in last 52 weeks?
    Mankind Pharma share price saw a 52 week high of Rs 2,490.00 and 52 week low of Rs 1,683.05.
  • 6. Who owns Mankind Pharma?
    Following are the key changes to Mankind Pharma shareholding:
    • Promoter holding have gone down from 76.5 (30 Sep 2023) to 74.87 (30 Jun 2024)
    • Domestic Institutional Investors holding has gone up from 4.56 (30 Sep 2023) to 9.94 (30 Jun 2024)
    • Foreign Institutional Investors holding has gone up from 4.18 (30 Sep 2023) to 11.58 (30 Jun 2024)
    • Other investor holding have gone down from 14.75 (30 Sep 2023) to 3.6 (30 Jun 2024)
  • 7. What are the Mankind Pharma quarterly results?
    On Consoldiated basis, Mankind Pharma reported a total income and profit of Rs 2994.02 Cr and Rs 536.49 respectively for quarter ending 2024-06-30. Total Income and profit for the year ending 2024-03-31 was Rs 10615.63 Cr and Rs 1912.90 Cr.
  • 8. What is the CAGR of Mankind Pharma?
    The CAGR of Mankind Pharma is 13.56.
  • 9. What are the key metrics to analyse Mankind Pharma Share Price?
    Key Metrics for Mankind Pharma are:
    • PE Ratio of Mankind Pharma is 49.52
    • Price/Sales ratio of Mankind Pharma is 8.90
    • Price to Book ratio of Mankind Pharma is 10.16
  • 10. Which are the key peers to Mankind Pharma?
    Top 10 Peers for Mankind Pharma are Aurobindo Pharma Ltd., Lupin Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., Divi's Laboratories Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd. and Biocon Ltd.
  • 11. What's the market capitalization of Mankind Pharma?
    Market Capitalization of Mankind Pharma stock is Rs 97,192.08 Cr.
  • 12. What is the PE & PB ratio of Mankind Pharma?
    The PE ratio of Mankind Pharma stands at 49.58, while the PB ratio is 10.16.

Equity Quick Links

Top Gainers
Top Losers
Stock Recommendations
Stock Screener
Candlestick Screener
Upcoming Dividends
Volume Shockers
Hourly losers
Hourly gainers
Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.

ADVERTISEMENT
Business News › Markets › Stocks › Stock Price Quotes › Mankind Pharma Ltd. Share Price

Browse Companies

ABCDEFGHIJKLMNOPQRSTUVWXYZ
123456789

Trending Now

Popular Categories

Hot on Web

In Case you missed it

More from our network

Download ET APP


Follow us on


Powered by

become a member

Terms of Use & Grievance Redressal Policy
DNPA Code of Ethics|Privacy Policy|Archive | Do Not Sell My Info|Delete Data|Feedback|

Copyright © 2024 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights:
Times Syndication Service